Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
|Articles|October 1, 2019
- BioPharm International-10-01-2019
- Volume 32
- Issue 10
BioPharm International, October 2019 Issue (PDF)
Click the title above to open the BioPharm International October 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Driving Improved Access to Biosimilarsalmost 7 years ago
Technology Redefines Continuous Processing Efficiencyalmost 7 years ago
Image Repair Must Start with the Root Causealmost 7 years ago
Best Practices for Selecting a Top-Quality Cell Linealmost 7 years ago
Data Integrity Violations Draw Strong FDA Rebukesalmost 7 years ago
ALCOA+ and Data Integrityalmost 7 years ago
Stability Indicating Methods for Aluminum Adsorbed Vaccine Productsalmost 7 years ago
Using Software in Process Validationalmost 7 years ago
Streamlining Operations in Fill/Finishalmost 7 years ago
Outsourcing Early Development OperationsAdvertisement
Related to this article
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
Advertisement
Advertisement